Depomed To Present AT JMP Securities 2014 Healthcare Conference

NEWARK, Calif., June 18, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the JMP Securities 2014 Healthcare Conference in New York City.

The presentation at the JMP conference is scheduled for 11:30 am ET (8:30 am PT) on Tuesday June 24, 2014.  The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

INVESTOR CONTACT:

August J. Moretti  

Depomed, Inc. 510.744.8000

amoretti@depomed.com

SOURCE Depomed, Inc.



RELATED LINKS
http://www.depomed.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.